Genetic variation in the myeloperoxidase gene and cognitive impairment in Multiple Sclerosis
2006

Genetic Variation in the Myeloperoxidase Gene and Cognitive Impairment in Multiple Sclerosis

Sample size: 465 publication Evidence: moderate

Author Information

Author(s): Manna I, Valentino P, La Russa A, Condino F, Nisticò R, Liguori M, Clodomiro A, Andreoli V, Pirritano D, Cittadella R, Quattrone A

Primary Institution: Institute of Neurological Science, National Research Council, Cosenza, Italy

Hypothesis

Does the -463 G/A polymorphism of the MPO gene contribute to cognitive impairment in patients with Multiple Sclerosis?

Conclusion

The study found that the MPO polymorphism is not a risk factor for cognitive impairment in patients with Multiple Sclerosis.

Supporting Evidence

  • 44% of patients were cognitively preserved, while 56% were cognitively impaired.
  • No significant difference was found in the number of failed neuropsychological tests among subjects with different polymorphic variants.
  • The study suggests that the MPO gene polymorphism does not confer a risk of cognitive impairment in MS patients.

Takeaway

This study looked at a gene that might affect thinking skills in people with Multiple Sclerosis, but it found that this gene doesn't seem to make a difference.

Methodology

The study used a PCR-RFLP based assay to analyze the MPO gene polymorphism in patients with MS.

Limitations

The study did not find significant differences in allele or genotype distributions between cognitively impaired and preserved MS patients.

Participant Demographics

The sample included 465 patients with Multiple Sclerosis, of which 204 were cognitively normal and 261 were cognitively impaired.

Statistical Information

P-Value

0.805

Confidence Interval

0.435–2.102

Statistical Significance

p = 0.805

Digital Object Identifier (DOI)

10.1186/1477-5751-5-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication